KPV

What is KPV?

KPV is a tripeptide (Lys-Pro-Val) derived from the C-terminal end of alpha-melanocyte stimulating hormone (alpha-MSH). Despite being only three amino acids, it retains the potent anti-inflammatory properties of the full hormone without melanocortin receptor activation. It has shown promise for inflammatory bowel disease, wound healing, and various inflammatory conditions.

What KPV Is Investigated For

KPV is investigated primarily as an anti-inflammatory tripeptide for inflammatory bowel disease, skin inflammation, wound healing, and broader inflammatory conditions — all mediated by direct intracellular NF-kB suppression rather than the melanocortin-receptor signaling of the parent alpha-MSH. The strongest evidence is mechanistic and preclinical: NF-kB inhibition is well-characterized, multiple rodent colitis models show reduced mucosal inflammation, and PepT1-mediated intestinal uptake provides a plausible route by which oral KPV reaches colonocytes. No Phase II or III RCTs have been published for IBD, skin inflammation, or any other indication, and human pharmacokinetics have not been rigorously characterized. Community and clinician dosing spans an order of magnitude (200–1,000 mcg/day across oral, SC, and topical routes) without any human dose-ranging anchor, and KPV has never been compared head-to-head with standard IBD therapies. The honest framing: mechanistically promising, historically interesting as the minimal anti-inflammatory fragment of alpha-MSH, and clinically unvalidated — patients with diagnosed inflammatory disease should not substitute KPV for evidence-based therapy.

History & Discovery

KPV's history traces back to work on alpha-melanocyte-stimulating hormone (alpha-MSH) in the 1980s and 1990s, when researchers investigating the anti-inflammatory activity of alpha-MSH sought to identify the minimal sequence required for anti-inflammatory effect. The C-terminal tripeptide Lys-Pro-Val (amino acids 11-13 of alpha-MSH) emerged as a small fragment that retained substantial anti-inflammatory activity while lacking the melanocortin receptor agonism responsible for alpha-MSH's pigmentary effects. Thomas Luger's group at the University of Münster and Markus Böhm's and Thomas Brzoska's subsequent work in the late 1990s and 2000s helped characterize KPV's cytokine-suppressing activity in keratinocytes and inflammatory cell models. Later work — notably Didier Merlin's group at Emory and Georgia State on PepT1-mediated intestinal uptake of KPV — established a mechanistic basis for why oral KPV might reach colonic enterocytes at pharmacologically relevant concentrations, supporting the subsequent interest in KPV as a candidate for inflammatory bowel disease. This translational thread produced multiple preclinical colitis-model studies and later targeted-delivery formulation work using hydrogels and nanoparticles. Despite several decades of preclinical interest and a well-characterized mechanism, KPV has not advanced to substantial human trials: no Phase II or III RCTs in IBD, skin inflammation, or other indications have been published. The peptide entered the compounding and research-chemical market relatively recently, and its clinical claim set significantly outruns the human evidence.

How It Works

KPV is a tiny anti-inflammatory peptide that enters cells and directly turns off the inflammation switch (NF-kB). It's particularly promising for gut inflammation because it can be taken orally and act directly on inflamed intestinal tissue.

KPV translocates into the cell cytoplasm and nucleus where it directly interacts with NF-kB p65 subunit, preventing its nuclear translocation and transcriptional activation of pro-inflammatory genes (TNF-alpha, IL-1beta, IL-6, IL-8). More recent work (Sung et al., 2025, Tissue & Cell) has extended the mechanism upstream: KPV inhibits ERK/p38 MAPK signaling and blocks caspase-1 activation, which positions it as a multi-node anti-inflammatory rather than a pure NF-kB blocker. That paper also established a new application context — KPV mitigates fine-particulate-matter-induced keratinocyte apoptosis and inflammation in HaCaT cells and 3D skin models, opening an environmental-skin-inflammation angle. It also inhibits inflammasome activation and reduces PGE2 production. In the gut, KPV is absorbed by colonocytes via PepT1 and reduces mucosal inflammation. Unlike full-length alpha-MSH, KPV does not activate MC1R-MC5R, avoiding melanogenic and other melanocortin-mediated effects.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about KPV:

• 01Human clinical efficacy — no Phase II or III RCTs have evaluated KPV for IBD, skin inflammation, or any other indication, so the gap between mechanistic promise and demonstrated human benefit is substantial.
• 02Pharmacokinetics in humans — absorption (particularly oral via PepT1), distribution, metabolism, and clearance have been characterized in rodents and cell models but not rigorously in humans.
• 03Optimal dosing and formulation — the range of doses discussed spans an order of magnitude, and whether standard capsules, enteric-coated formulations, or targeted-delivery systems (hydrogels, nanoparticles studied in preclinical work) are required for clinical efficacy is unresolved.
• 04Long-term safety — even short-term human safety observation is limited, and chronic-use data is absent.
• 05Comparative effectiveness vs. established therapies — KPV has never been compared head-to-head with standard IBD treatments (5-ASA, corticosteroids, biologics) in humans, leaving its place in a therapeutic hierarchy entirely undefined.
• 06Whether subcutaneous dosing produces meaningful systemic exposure — mechanistic rationale is strongest for local routes (oral for gut, topical for skin), and systemic pharmacodynamics at typical injected doses is not characterized.

Forms & Administration

Oral capsules (for gut inflammation), SC injection, or topical application. Oral doses typically 200-500mcg. SC: 200-500mcg/day. Can be compounded into various formulations. All injectable peptides should only be administered under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

These numbers are not a prescription. KPV is not FDA-approved for any medical condition. Any actual use should be under the direct supervision of a qualified healthcare provider, and KPV should not be used to replace standard-of-care therapy for diagnosed inflammatory conditions without clinician guidance.

Timeline of Effects

Common Questions

Who KPV Is NOT For

Drug & Supplement Interactions

Documented human drug interactions for KPV are absent; clinical pharmacology studies of this tripeptide have not been published. What follows is theoretical. Because KPV's primary mechanism is suppression of NF-kB and associated cytokine signaling, theoretical interactions exist with other anti-inflammatory and immunomodulatory agents — corticosteroids, biologic DMARDs (anti-TNF agents, anti-IL-6, anti-IL-17), small-molecule immunosuppressants (JAK inhibitors, calcineurin inhibitors) — in the direction of additive immune suppression. In most clinical contexts this would be subtle at KPV's typical doses, but patients on biologics for IBD or autoimmune disease should not add KPV without their treating specialist's input. KPV is absorbed in the intestine via PepT1, which also handles certain peptide-based drugs (cephalosporin antibiotics, ACE inhibitors with peptide-like structure, some antivirals). Competitive absorption is theoretical and not characterized clinically. Patients on any regular medication should disclose KPV use to their prescribing clinician, because absence of documented interaction reflects absence of study rather than absence of risk.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions